Compositions comprising PCSK9-binding molecules and methods of use
AssigneeLib Therapeutics, LLC.
InventorsTracy S. Mitchell, Richard Mealey
Life of this patent
Estimating the term…
Abstract
The present disclosure provides pharmaceutical compositions comprising fibronectin based scaffold domain proteins that bind, for example, proprotein convertase subtilisin kexin-9 (PCSK9).
Claims17
A composition comprising at least one unit dose of a PCSK9-binding fusion protein having the amino acid sequence of SEQ ID NO:3, the unit dose containing from about 250 mg to about 350 mg of the PCSK9-binding fusion protein formulated at a concentration of at least 200 mg/mL, and a pharmaceutically-acceptable carrier comprising from about 1 mg/mL to about 10 mg/mL L-Histidine/L-Histidine monohydrochloride maintaining a pH of about 6.8, and from about 6 mg/mL to about 12 mg/mL sodium chloride.
A method for treating a PCSK9-related disorder, comprising:
- administering to a subject in need, a unit dose of a PCSK9-binding fusion protein having the amino acid sequence of SEQ ID NO:3, the unit dose containing from about 250 mg to about 350 mg of the PCSK9-binding fusion protein formulated at a concentration of at least 200 mg/mL in a pharmaceutically-acceptable carrier comprising from about 1 mg/mL to about 10 mg/mL L-Histidine/L-Histidine monohydrochloride maintaining a pH of about 6.8, and from about 6 mg/mL to about 12 mg/mL sodium chloride;
- wherein a unit dose is administered subcutaneously about every 4 weeks.
Dependencies are inferred from the claim text.